ModeX is dedicated to developing next-generation multispecific biologics for cancers and infectious diseases.
ModeX’s platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency against complex diseases.
Our Journey
We are a leading developer of multispecific medicines and vaccines. Our capabilities are built on decades of collaboration amongst our team at the highest levels of medical research and drug development. We have achieved several breakthroughs in recent years that drive our work to create medicines that can transform lives.
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck.
ModeX secures $35 Million BARDA supplement to develop COVID multispecific antibodies and $16 Million to initiate influenza program.
OPKO Health’s ModeX appoints Dr. Giovanni Abbadessa, MD, PhD, as Chief Medical Officer as pipeline advances into clinical development.
ModeX begins Phase 1/2a clinical trial of first-in-class tetraspecific T cell engager (MDX2001) for the treatment of advanced cancer with solid tumors dosing the first patient in August of 2024.
AIDS Clinical Trial Group (ACTG), a clinical trials network funded by the National Institute of Allergy and Infectious Diseases, presents results from phase 1 study of ModeX trispecific antibody for the treatment and prevention of HIV.
OPKO Health’s ModeX enters into exclusive worldwide license and collaboration agreement with Merck to develop Epstein-Barr Virus (EBV) vaccine candidate.
ModeX secures BARDA contract to develop novel multispecific antibodies against viral infectious disease threats.
Members of our team publish in Nature Communications describing the ability of a trispecific antibody to activate latent HIV, increase immune activation and enhance the killing of latently-infected cells.
ModeX becomes a wholly owned subsidiary of OPKO Health, a diverse healthcare company focused on improving patients’ lives
ModeX vaccine R&D is published in Science Translational Medicine, describing the ability of our EBV ferritin nanoparticle vaccine technology to induce neutralizing antibodies that block infection and confer immunity
ModeX immuno-oncology R&D is published in Nature, describing the anti-tumor activity of one of our trispecific T-cell engager antibodies
ModeX welcomes new industry-leading leadership including John Mascola as Chief Scientific Officer, Ji Zhang as Chief Operating Officer and Vijay Chhajlani as Chief Technology Officer
ModeX reveals its core multispecific antibody platform: MSTAR (Synergistic Targeting of Antigens and Receptors)
ModeX initiates clinical study of first-generation trispecific antibody technology against HIV
ModeX is founded by eminent medical innovators Gary Nabel and Elias Zerhouni as well as R&D leaders Zhi-yong Yang, Ronnie Wei, Chih-Jen Wei and Elizabeth Nabel
Members of our team publish in Nature Cancer describing the ability of a trispecific antibody to enhance the therapeutic efficacy of tumor-directed T cells
Members of our team publish in Science, describing the ability of a trispecific antibody to provide treatment and prevention of HIV/AIDS in non-human primates
While at Sanofi, the team creates a trispecific antibody that engages three targets with a single antibody
Drs. Elias Zerhouni and Gary Nabel create Breakthrough Laboratories within Sanofi Global R&D to explore first-in-class technologies and concepts
Leading with experience
OPKO Health
As our parent company, OPKO Health provides the operational resources to accelerate the development of our platform technologies and portfolio. ModeX benefits from the support and guidance of Dr. Phillip Frost, a visionary physician entrepreneur, and the OPKO leadership team who recognize the transformative potential of multispecific medicines. ModeX brings to OPKO groundbreaking multispecific biologic platforms and expertise through our management team’s world-leading biomedical innovation leadership. ModeX and OPKO share a vision of transforming medicine to benefit patients.
In combination with OPKO’s deep operational and development capabilities, we are strongly positioned together to move multiple programs in parallel through clinical development and accelerate our strategy to deliver a portfolio of first-in-class multispecific antibodies for cancer and infectious disease.
